Digitalized Surveillance Management for Liver Cancer Risk Population in Improving Eearly Diagnosis Efficancy in Chinese Population (dSEARCH)

Sponsor
Ruijin Hospital
Study ID
NCT05870969
Status
Recruiting
Apply to this trial

Conditions

  • Carcinoma, Hepatocellular
  • Cirrhosis, Liver
  • Hepatitis B, Chronic
  • Hepatitis C, Chronic
  • Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Liver cancer surveillance every 3 months — BEHAVIORAL
    Follow up every 3 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
  • Liver cancer surveillance every 6 months — BEHAVIORAL
    Follow up every 6 months for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam
  • Liver cancer surveillance annually — BEHAVIORAL
    Follow up annually for liver cancer surveillance, including but not limited to serum AFP test and ultrasound exam

Study Details

The goal of this study is to evaluate whether the standardized liver cancer risk stratification management can effectively improve the early diagnosis rate of liver cancer in the targeted risk population in China.

Key Dates

First listed
May 23, 2023
Start date
Mar 1, 2023
Status verified
May 2023
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
20,000 participants (estimated)

Arms

  • Arm: Patients with very high risk for HCC according local guideline
  • Arm: Patients with high risk for HCC according local guideline
  • Arm: Patients with medium risk for HCC according local guideline
  • Arm: Patients with low risk for HCC according local guideline

Primary Outcome Measure

Early diagnosis rate of HCC patients [ Time Frame: Follow up up to three years for HCC occurance. ]

Central Contacts

Related Studies